

Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis

John Danesh, Peter Whincup, Mary Walker, Lucy Lennon, Andrew Thomson, Paul Appleby, Yuk-ki Wong, Martine Bernardes-Silva, Michael Ward

Editorial by Koenig

Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX2 6HE

John Danesh
clinical research fellow

Department of Public Health Sciences, St George's Hospital Medical School, London SW17 0RE

Peter Whincup
professor

Department of Population Sciences and Primary Care, Royal Free and University College London Medical School, London NW3 2PF

Mary Walker
senior lecturer

Lucy Lennon
research assistant

Andrew Thomson
computer programmer

Imperial Cancer Research Fund Cancer Epidemiology Unit, Oxford OX2 6HE

Paul Appleby
statistician

Departments of Cardiology and Molecular Microbiology, University of Southampton, Southampton SO16 6YD

Yuk-ki Wong
research registrar

Martine Bernardes-Silva
research scientist

Michael Ward
professor

Correspondence to: J Danesh

BMJ 2000;321:208-13



Further details of the meta-analysis are available on the BMJ's website

Abstract

Objective To examine the association between coronary heart disease and serum markers of chronic *Chlamydia pneumoniae* infection.

Design "Nested" case-control analysis in a prospective cohort study and an updated meta-analysis of previous relevant studies.

Setting General practices in 18 towns in Britain.

Participants Of the 5661 men aged 40-59 who provided blood samples during 1978-80, 496 men who died from coronary heart disease or had non-fatal myocardial infarction and 989 men who had not developed coronary heart disease by 1996 were included.

Main outcome measures IgG serum antibodies to *C pneumoniae* in baseline samples; details of fatal and non-fatal coronary heart disease from medical records and death certificates.

Results 200 (40%) of the 496 men with coronary heart disease were in the top third of *C pneumoniae* titres compared with 329 (33%) of the 989 controls. The corresponding odds ratio for coronary heart disease was 1.66 (95% confidence interval 1.25 to 2.21), which fell to 1.22 (0.82 to 1.82) after adjustment for smoking and indicators of socioeconomic status. No strong associations were observed between *C pneumoniae* IgG titres and blood lipid concentrations, blood pressure, or plasma homocysteine concentration. In aggregate, the present study and 14 other prospective studies of *C pneumoniae* IgG titres included 3169 cases, yielding a combined odds ratio of 1.15 (0.97 to 1.36), with no significant heterogeneity among the separate studies ($\chi^2 = 10.5$, $df = 14$; $P > 0.1$).

Conclusion This study, together with a meta-analysis of previous prospective studies, reliably excludes the existence of any strong association between *C pneumoniae* IgG titres and incident coronary heart disease. Further studies are required, however, to confirm or refute any modest association that may exist, particularly at younger ages.

Introduction

A study published in 1988 proposed that *Chlamydia pneumoniae* infection was an avoidable cause of coronary heart disease.¹ Since then, systematic reviews have identified several dozen additional studies of *C pneumoniae* markers and vascular disease.²⁻⁴ Although some reports have suggested twofold or larger odds ratios for coronary heart disease in people with markers of chronic *C pneumoniae* infection, these studies have generally been small, retrospective, or liable to biases.²⁻⁴ We report a study of 496 cases of coronary heart disease and 989 controls "nested" in a prospective cohort of British men monitored for 16

years. We also conducted an updated meta-analysis of other prospective studies to place our results in context.

Participants and methods

Cases and controls

During 1978-80, 7735 men aged 40-59 (response rate 78%) were randomly selected from general practice registers in each of 24 British towns and entered in the British Regional Heart Study.⁵ Nurses administered epidemiological questionnaires, made physical measurements, and recorded an electrocardiogram. Non-fasting venous blood samples were collected in 5661 men in 18 of the towns and stored at -20°C for subsequent analysis. Further questionnaires were posted after five years (98% response among survivors) and 12 years of follow up (90% response among survivors) that asked about car ownership and childhood social circumstances (father's social class and childhood household amenities) respectively. All men have been monitored since entry for death from all causes and for cardiovascular morbidity, with a loss to follow up of less than 1%.⁵ Cases in our study were men who had fatal coronary events or non-fatal myocardial infarction between the beginning of follow up and December 1995 and who had a stored serum sample available for analysis. Fatal cases of coronary heart disease were ascertained through NHS central registers on the basis of a death certificate with International Classification of Disease (ICD-9) codes 410-414. Non-fatal myocardial infarction was based on reports from general practitioners, supplemented by evidence from general practice records, meeting World Health Organization criteria.⁵ Of 507 potential cases (223 deaths from coronary heart disease and 284 non-fatal myocardial infarctions), 496 had *C pneumoniae* measurements available. A total of 1026 controls, who were "frequency matched" to cases on town of residence and age in five year bands, were randomly selected from among men who had survived to the end of the study period without a myocardial infarction; 989 of these controls had *C pneumoniae* measurements available.

Laboratory methods

Laboratory workers unaware of the disease status of the participants analysed blood samples for *C pneumoniae* using whole organism antigen and time resolved fluorimetry.⁶ The assay showed good agreement with microimmunofluorescence in a validation study of 480 people (intra-assay and interassay coefficients of variation were 4% and 8%). Serum lipid concentration, albumin concentration, leucocyte count, and packed cell volume were measured with standard assays, and C reactive protein and serum amyloid A concentrations were determined by sensitive enzyme immunoassays.⁵

Statistical methods and systematic review

We compared case and control groups using unmatched stratified logistic regression fitted by unconditional maximum likelihood (Stata Corporation, College Station, Texas, USA). Adjusted analyses included the following explanatory variables: age; cigarette smoking habit (never, former, current); daily cigarette consumption; non-fasting blood concentrations of total cholesterol, high density lipoprotein cholesterol, and triglyceride; markers of current social class (registrar general's 1980 classification with a separate category for armed forces); housing tenure (owner, private rent, council rent); marital status; current car ownership; father's occupation (manual, non-manual); and childhood social circumstances (father's occupation, family car ownership, bathroom in house, hot water tap in house, bedroom sharing). We prespecified analysis of *C pneumoniae* IgG titres by thirds of the values in controls—that is, the top third was defined as seropositive and the bottom third as seronegative. Previous systematic reviews suggested the need for adjustments for smoking and indicators of socioeconomic status in adulthood and childhood to help reduce any residual confounding in studies of coronary heart disease and persistent infective agents, and some previous studies of *C pneumoniae* infection and coronary heart disease have reported adjustments for indicators of social class both in adult life and in childhood (see Discussion).²⁻⁵ We therefore prespecified that odds ratios would be reported both with and without such adjustments. For analyses of *C pneumoniae* IgG titres with a variety of known and suspected risk factors, emphasis was given to differences greater than 2.6 standard deviations ($P=0.01$) to make some allowance for multiple comparisons.

Methods to identify studies for an updated meta-analysis of prospective studies of coronary heart disease and *C pneumoniae* IgG titres or IgA titres published before May 2000 have been described.²⁻³ Cases were compared with controls only within the same studies to avoid potential biases (see *BMJ's* website for full details).

Results

As would be expected, we found highly significant differences between cases and controls with respect to various known vascular risk factors such as smoking, obesity, blood pressure, and blood lipid concentration (table 1). *C pneumoniae* IgG titres were significantly associated with age and leucocyte count (table 2). Among cases, titres were also associated with smoking status, although this was attenuated by adjustment for indicators of socioeconomic status (data not shown). No significant associations were observed between *C pneumoniae* IgG titres and various indicators of socioeconomic status and values of blood lipids, blood pressure, plasma homocysteine, C reactive protein, serum amyloid A protein, albumin, and packed cell volume.

Two hundred (40%) of the 496 cases had serum IgG titres for *C pneumoniae* in the top third compared with 329 (33%) of 989 controls (table 3). This difference yielded an odds ratio for coronary heart disease of 1.66 (95% confidence interval 1.25 to 2.21) in men in the top third of baseline *C pneumoniae* IgG titres compared

Table 1 Baseline characteristics of men with coronary heart disease and of controls matched for age, sex, and town. Values are mean (SD) unless stated otherwise

Characteristic	Cases (n=507)	Controls (n=1026)	P value
Questionnaire			
Age (years)	52.2 (5.3)	52.2 (5.3)	Matched
No (%) of current smokers	268 (53)	436 (43)	<0.0001
No (%) with evidence of coronary disease*	177 (35)	204 (20)	<0.0001
No (%) with treated diabetes	12 (2)	15 (1)	NS
No (%) consuming >2 drinks alcohol/day	110 (22)	232 (23)	NS
No (%) with occupation in social classes I-II	112 (22)	280 (27)	0.03
No (%) of home owners†	275 (64)	667 (69)	0.03
Physical measurements			
Body mass index (kg/m ²)	25.8 (3.4)	25.3 (3.3)	0.008
Height (cm)	1.71 (0.06)	1.72 (0.07)	0.002
Weight (kg)	76.3 (11.4)	75.8 (11.2)	NS
Systolic blood pressure (mm Hg)	151 (21)	147 (21)	<0.0001
Diastolic blood pressure (mm Hg)	86 (14)	83 (13)	<0.0001
Forced expiratory volume in 1 second (l)	308 (68)	326 (77)	<0.0001
Blood sample			
Total cholesterol (mmol/l)	6.63 (1.10)	6.20 (0.99)	<0.0001
HDL cholesterol (mmol/l)	1.10 (0.28)	1.15 (0.29)	0.0003
Triglyceride (mmol/l)	2.26 (1.33)	1.93 (1.22)	<0.0001

*Evidence of ischaemia on baseline electrocardiogram or reported history of angina or myocardial infarction.
†Information on home ownership was available for only 431 cases and 964 controls.

Table 2 Comparisons of levels of risk factors and other characteristics in controls by thirds of *C pneumoniae* IgG titres. Values are means (SD) unless stated otherwise

	Top (n=329)	Middle (n=321)	Bottom (n=329)	†	‡
Age (years)	52.6 (5.5)	52.4 (5.0)	51.6 (5.4)	2.5	2.8*
No (%) of current smokers	160 (49)	131 (40)	131 (40)	1.4	1.8
No (%) consuming >2 alcohol drinks/day	87 (26)	67 (20)	72 (22)	1.0	1.4
No (%) with evidence of coronary heart disease at baseline	66 (20)	61 (18)	67 (20)	0.4	0.9
Physical measurements					
Body mass index (kg/m ²)	25.3 (3.4)	25.5 (3.3)	25.1 (3.2)	1.0	1.2
Height (cm)	172 (7)	173 (7)	174 (6)	1.5	1.5
Weight (kg)	75 (12)	76 (11)	76 (11)	0.0	0.1
Systolic blood pressure (mmHg)	148 (20)	147 (21)	146 (21)	0.4	1.0
Diastolic blood pressure (mmHg)	83 (13)	83 (14)	82 (13)	0.2	0.5
Forced expiratory volume in 1 second (l)	316 (80)	326 (79)	334 (70)	1.4	1.8
Blood sample					
Log ₁₀ C reactive protein (mg/l)	0.21 (0.54)	0.18 (0.52)	0.08 (0.52)	2.8	2.3
Log ₁₀ serum amyloid A protein (mg/l)	0.85 (0.31)	0.85 (0.32)	0.82 (0.28)	1.1	0.4
Albumin (g/l)	44.3 (2.4)	44.6 (2.6)	44.6 (2.3)	0.9	1.1
White cell count (×10 ⁹ /l)	7.3 (1.7)	7.3 (1.8)	7.1 (1.8)	2.9	3.3**
Total cholesterol (mmol/l)	6.15 (0.98)	6.17 (1.02)	6.27 (0.97)	0.7	0.2
HDL cholesterol (mmol/l)	1.17 (0.32)	1.13 (0.27)	1.17 (0.27)	0.5	0.0
Triglyceride (mmol/l)	1.85 (1.10)	1.98 (1.12)	1.94 (1.27)	1.0	0.6
Homocysteine (μmol/l)	15.2 (10.1)	15.1 (9.8)	14.6 (7.6)	0.1	0.1
Packed cell volume (%)	42.3 (9.5)	43.1 (7.8)	42.5 (8.5)	0.6	1.1
Socioeconomic factors§					
No (%) of subjects:					
Non-manual occupation	80 (24)	97 (29)	96 (29)	1.1	1.4
Homeowner	211 (68)	215 (70)	215 (69)	0.1	0.2
Married	297 (90)	284 (86)	291 (88)	0.0	0.0
Car owner	227 (73)	236 (77)	248 (79)	1.2	1.0
Father with non-manual job	193 (80)	188 (74)	189 (73)	0.5	0.4
Family owned a car	26 (10)	39 (14)	45 (17)	0.6	0.7
Bathroom in house	126 (49)	131 (49)	130 (48)	1.2	1.3
Hot water tap in house	128 (50)	137 (52)	134 (50)	1.5	1.5
Bedroom shared	172 (67)	179 (67)	167 (62)	0.1	0.2

* $P<0.01$, ** $P<0.001$.

†‡ tests derived from regression of *C pneumoniae* IgG titres on each characteristic separately with adjustment for age and town only.

‡ tests derived from regression of *C pneumoniae* IgG titres on each characteristic separately with adjustment for age, town, body mass index, and markers of socioeconomic status.

§Information on some factors available only in a subset of controls: car ownership 964, father's occupation 753, family car ownership 789, bathroom in house 791, hot water supply 789, bedroom sharing 790, plasma homocysteine 416.

Table 3 Odds of coronary heart disease in men who were IgG seropositive for *C pneumoniae* relative to those who were seronegative

Thirds of IgG titres in controls ($\times 10^6$ fluorescent count)	No of cases	No of controls	Odds ratio (95% CI) with adjustments as indicated			
			Age and town	Age, town, and smoking	Age, town, smoking, and adult socioeconomic status*	Age, town, smoking, and childhood† and socioeconomic status
All 496 cases and 989 controls						
Top third (>213)	200	329	1.66 (1.25 to 2.21)	1.61 (1.21 to 2.15)	1.59 (1.17 to 2.16)	1.22 (0.82 to 1.82)
Middle third (166-213)	169	331	1.38 (1.04 to 1.82)	1.36 (1.03 to 1.80)	1.36 (1.00 to 1.84)	1.06 (0.72 to 1.57)
Bottom third (<166)	127	329	1.0	1.0	1.0	1.0
Only those without evidence of coronary heart disease at baseline						
Top third (>213)	116	262	1.34 (0.95 to 1.89)	1.31 (0.93 to 1.86)	1.30 (0.90 to 1.86)	0.98 (0.63 to 1.55)
Middle third (166-213)	114	270	1.29 (0.93 to 1.80)	1.29 (0.92 to 1.80)	1.29 (0.90 to 1.83)	1.06 (0.68 to 1.63)
Bottom third (<166)	89	261	1.0	1.0	1.0	1.0

Individuals with titres in the bottom third of the distribution in controls were regarded as seronegative.

*Smoking, occupation, housing tenure, marital status, car ownership.

†Father's social class, family car ownership, bathroom in house, hot water tap in house, bedroom sharing, height.

with men in the bottom third. The odds ratio was 1.59 (1.17 to 2.16) after adjustment for smoking and indicators of adult socioeconomic status and 1.22 (0.82 to 1.82) after additional adjustment for indicators of childhood socioeconomic status. These results were not materially changed when the analyses were adjusted for additional classic risk factors or when they were restricted to the 319 cases and 793 controls with no evidence of coronary heart disease at baseline (table 3) or to the 221 cases and 750 controls who had complete information on all reported markers of childhood socioeconomic status. Varying the cut-off titre did not materially alter the estimates.

Discussion

Previous retrospective serological studies have suggested that chronic *C pneumoniae* infection is an important cause of coronary heart disease in the general population,¹ but this hypothesis has not been adequately tested in larger prospective studies. In comparison with retrospective studies, prospective studies should reduce selection biases, minimise any influence of disease itself on the factor being investigated, and generally include better adjustment for potential confounding factors—for example, only about half of the retrospective studies of *C pneumoniae* and coronary heart disease published before 1998 reported adjustment for cigarette smoking.^{2,3} Our prospective, community based study, with 16 years of mean follow up, included more coronary heart disease cases than all but one previous study.⁷ We found an odds ratio for coronary heart disease of 1.59 (1.17 to 2.16) in men with high baseline *C pneumoniae* IgG titres after adjusting for smoking and markers of adult social class and an odds ratio of 1.22 (0.82 to 1.82) after additional adjustment for markers of childhood social class. The partially adjusted and fully adjusted odds ratios were statistically compatible with each other (because of relatively wide, overlapping confidence intervals) and were also compatible with either a moderately positive association or no association at all. We therefore conducted a systematic review of previous relevant studies of *C pneumoniae* and coronary heart disease to assess further any association.

Meta-analysis

Including the present study, we identified 15 prospective studies of *C pneumoniae* IgG titres and coronary

heart disease up to May 2000.⁷⁻²⁰ The studies included a total of 3169 cases of non-fatal myocardial infarction or death from coronary heart disease; the weighted mean age at baseline was 56 years with a weighted mean follow up of 10 years. All adjusted for smoking and some other classic risk factors, but only seven (including our study) reported adjustment for markers of adult socioeconomic status⁷⁻¹² and only two for markers of childhood social class.⁹ Ten of the studies used microimmunofluorescence assays (seven studies used $\geq 1:64$ as a cut-off titre for seropositivity,^{8,9,11,12,15,18,20} one study used $\geq 1:128$,¹³ one used $\geq 1:32$,¹⁷ and one did not specify the cut off¹⁶), and five used other methods (two used enzyme linked immunoassays,^{10,19} two used time resolved fluorimetry,⁷ and one did not specify the exact method¹⁴). Despite these differences, there was no significant heterogeneity among the 15 studies ($\chi^2 = 10.5$, $df = 14$; $P > 0.1$), and a combined analysis yielded an odds ratio of 1.15 (95% confidence interval 0.97 to 1.36) for coronary heart disease (figure).

Subsidiary analyses yielded a combined odds ratio of 1.15 (0.84 to 1.57) in the eight studies (822 cases) that did not adjust for indicators of adult socioeconomic status¹³⁻²⁰ and an odds ratio of 1.16 (0.95 to 1.41) in the 13 studies (2395 cases) that did not adjust for indicators of childhood socioeconomic status.^{7,8,10-20} Moreover, if the partially adjusted odds ratio for our study was used in the meta-analysis of all 15 studies (instead of the fully adjusted odds ratio), the combined odds ratio was still 1.19 (0.99 to 1.41). Similar results were obtained in the 10 studies (1521 cases) that used microimmunofluorescence assays (combined odds ratio 1.11 (0.87 to 1.42)),^{8,9,11-13,15-20} and in the nine studies (1816 cases) that reported risk in relation to *C pneumoniae* IgA titres (combined odds ratio of 1.13 (0.90 to 1.41)).^{7,9,10,13,15,17-19,21} Again, there was no significant heterogeneity among studies in any of these subsidiary analyses.

Our meta-analysis therefore reliably excludes any strong association between *C pneumoniae* IgG titres (or IgA titres) and coronary heart disease. Existing data are, however, insufficient to assess reliably any odds ratios weaker than about 1.5. Moreover, published studies have not corrected for possible underestimation due to fluctuations in serum antibody titres within individuals over time (as *C pneumoniae* seropositivity may disappear and recur²²). Further studies are therefore required to confirm or refute any more mod-

Table 4 Some larger randomised trials currently in progress of antichlamydial strategies for prevention of coronary heart disease

Study	Location	Planned size	Entry criteria	Drugs/duration (months)	Follow up (years)
ACES*	United States	4000	Previous myocardial infarction or coronary revascularisation	Azithromycin/12	4
PROVEIT*	United States	4000	Acute coronary syndrome	Gatifloxacin/18	1.5
WIZARD†	United States	3800	Previous myocardial infarction or coronary revascularisation	Azithromycin/3	3
MARBLE*	United Kingdom	1300	Waiting for coronary artery bypass graft surgery	Azithromycin/3	1
STAMINA*	United Kingdom	600	Previous myocardial infarction	Azithromycin plus drugs against <i>Helicobacter pylori</i> /0.5	1.5

*Patients randomised irrespective of *C pneumoniae* serostatus.

†Only patients with *C pneumoniae* IgG titres $\geq 1:16$ are to be randomised. In May 2000 WIZARD investigators announced possible enlargement of trial's sample size or longer follow up, or both, to increase its statistical power.

est association that may exist, particularly at younger ages, when associations may be stronger than at older ages.²²

Implications for randomised trials of antibiotic treatments


Three randomised placebo controlled trials of antichlamydial treatments have reported on coronary heart disease events,^{20–23–25} each including a few hundred patients with a history of coronary heart disease. All three trials put patients on brief courses of oral macrolides or macrolide derivatives (antibiotics with antichlamydial and, perhaps, anti-inflammatory effects). The first recorded only eight coronary events and yielded a non-significant result (although the investigators reported a fourfold reduction in coronary heart disease on the basis of an inappropriate non-randomised comparison).²⁰ The second published trial recorded 22 events and also gave non-significant results after six months of follow up.²³ Hence, in retrospect, this study's earlier claim of a fourfold reduction in coronary heart disease at one month was largely or wholly due to chance or selective reporting of an interim analysis.²⁴ The third trial (also reported in an interim analysis) recorded 16 events and had non-significant results.²⁵

Several trials are now in progress with larger sample sizes, lengthier antibiotic treatment periods, and more prolonged follow up (table 4). But even these trials may be able to provide only limited information about any effects of antichlamydial treatment in coronary heart disease. Our meta-analysis of prospective seroepidemiological studies creates considerable doubt about the existence of any independent association between persistent *C pneumoniae* infection and coronary heart disease. The combined odds ratio was only 1.15 (0.97 to 1.36), which is much weaker than the combined weighted odds ratio for atherosclerosis of 20 (15 to 32) obtained from pathology based studies that have assessed human arterial specimens for endovascular markers of *C pneumoniae* (DNA, antigens, elementary bodies, or viable organisms).^{2–4}

What might account for this 20-fold discrepancy? Pathology based studies have been retrospective (thereby creating uncertainty about whether local *C pneumoniae* infection is a cause or consequence of atheroma), whereas the prospective serological studies assessed evidence of infection several years before the diagnosis of coronary heart disease. Most pathology based studies have also been prone to selection biases and lacked any adjustment for possible confounders such as age, sex, and smoking,^{2–4} but this could not

plausibly explain much of the 20-fold difference. It is also unclear to what extent the discrepancy can be accounted for by the different definitions of vascular disease (atheroma versus major coronary events) and the different markers of infection (endovascular markers such as DNA and antigens versus circulating antibody titres) used in these different sets of studies.

Such epidemiological uncertainties have implications for the numbers needed in clinical trials. If the 20-fold odds ratio reported in the pathology based studies mainly reflected a causal effect that was largely reversible (rather than some artefact of confounding or reverse association), then antichlamydial treatments might be expected to reduce coronary event rates substantially. To confirm or refute such large effects should require trials only of similar size to the three previously reported trials (although, depending on the speed at which the risk reversed, follow up might need to be much longer). If, however, the prospective serological studies provide a more reliable guide to the likely strength of any association between *C pneumoniae* and coronary heart disease, the trials would need to be much larger than those previously conducted or



Prospective studies of *Chlamydia pneumoniae* IgG titres and coronary heart disease. Black squares indicate the odds ratio in each study, with the square size proportional to the number of cases and horizontal lines representing 99% confidence intervals. The combined odds ratio and its 95% confidence interval are indicated by a diamond. Degree of adjustment for possible confounders is denoted as +++ for age, sex, smoking, and some other classic vascular risk factors, and ++++ for these plus markers of socioeconomic status (or studies done in socially homogeneous groups). Some studies did not provide separate results for non-fatal myocardial infarction or death from coronary heart disease (instead reporting coronary heart disease results combined with those for stroke^{12–14} or angina^{19–20}). These studies, however, comprised only about 10% of the total cases in this meta-analysis, and most of the cases in these studies had major coronary events

What is already known on this topic

Persistent infection with *Chlamydia pneumoniae* has been suggested to be an avoidable cause of coronary heart disease

Most previous studies on the topic have been small and prone to biases

What this study adds

Baseline *C pneumoniae* IgG concentrations were not strongly associated with major coronary events or with classic or suspected risk factors

Updated meta-analysis of relevant prospective studies gave a combined odds ratio for heart disease of only about 1.1, which was not significant

Substantial uncertainty exists about any independent association between *Chlamydia pneumoniae* infection and heart disease

currently in progress. Even if there is a 10% excess risk due to *C pneumoniae* that is fully reversible by antibiotics, none of the existing trials would be large enough to confirm or refute its existence (the largest current trials cannot detect reductions in coronary events that are less than 25%; table 4).

Conclusion

Since 1997, the number of cases of coronary heart disease in prospective studies of *C pneumoniae* IgG titres has increased 10-fold to over 3000 cases, with our study being one of the largest. Unlike previous retrospective studies, more reliable prospective data indicate that *C pneumoniae* IgG titres are not strongly associated with coronary heart disease.

We thank H Refsum and P Ueland for the homocysteine assays; J R Gallimore and M B Pepys for the C reactive protein and serum amyloid A protein assays; J Atherton and C Hawkey for *H pylori* assays; and J John for valuable help. Professor G Shaper established the British Regional Heart Study.

Contributors: The study was designed and conducted by the British Regional Heart Study collaborative group. All the named authors contributed to the analysis and interpretation of these data and to writing the paper. JD and PW are the guarantors.

Funding: The British Regional Heart Study is a British Heart Foundation research group and also receives support from the Department of Health. JD was supported by a Merton College fellowship and a Frohlich award.

Competing interests: None declared.

- Saikku P, Leionen M, Mattila K, Ekman MR, Nieminen MS, Makepel PH, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. *Lancet* 1988;ii:983-6.
- Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? *Lancet* 1997;350:430-6.
- Danesh J, Appleby P. Persistent infection and vascular disease: a systematic review. *Expert Opin Invest Drugs* 1998;7:691-713.
- Wong YK, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. *Heart* 1999;81:232-8.
- Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Atherton J. Prospective study of virulent strains of *Helicobacter pylori* and coronary heart disease. *Circulation* 2000;101:1647-52.
- Wong YK, Sueur JM, Fall CHD, Orfila J, Ward ME. The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluorescent immunoassay for measuring antibodies against *Chlamydia pneumoniae*. *J Clin Pathol* 1999;2:99-103.
- Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: results from a large prospective study. *BMJ* 2000;321:204-7.

- Ridker PM, Kundsinn RB, Stampfer MJ, Poulain S, Hennekens CH. Prospective study of *Chlamydia pneumoniae* IgG seropositivity and risks of future myocardial infarction. *Circulation* 1999;99:1161-4.
- Strachan DP, Carrington D, Mendall MA, Ballam L, Morris J, Butland BK, et al. Relation of *Chlamydia pneumoniae* serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. *BMJ* 1999;318:1035-40.
- Tavendale R, Parratt D, Brook RA, Tunstall-Pedoe H. Antibodies to *Chlamydia pneumoniae* do not predict subsequent CHD in the Scottish Heart Health and MONICA studies [Abstract No P2221]. *Eur Heart J* 1999;20(suppl):450. (<http://ex2.excerptamedica.com/99esc/>)
- Nieto FJ, Folsom A, Sorlie P, Grayston JT, Wang S, Chambless LE. *Chlamydia pneumoniae* infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. *Am J Epidemiol* 1999;150:149-56.
- Ridker PM, Hennekens CH, Buring JE, Kundsinn RB, Shih J. Baseline IgG antibody titers to *Chlamydia pneumoniae*, *Helicobacter pylori*, herpes simplex virus, and cytomegalovirus and the risk of future cardiovascular disease in women. *Ann Intern Med* 1999;131:573-7.
- Miettinen H, Lehto S, Saikku P, Haffner SM, Rannemaa T, Pyorala K, et al. Association of *Chlamydia pneumoniae* and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. *Eur Heart J* 1996;17:682-8.
- Haider AW, Wilson PWF, Larson MG, Sutherland P, Evans JC, O'Donnell CJ, et al. *Chlamydia*, *H pylori* and cytomegalovirus seropositivity and risk of cardiovascular disease: the Framingham heart study. *J Am Coll Cardiol* 1999;33(suppl A):314A.
- Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, et al. Chronic *Chlamydia pneumoniae* infection as a risk factor for coronary heart disease in the Helsinki heart study. *Ann Intern Med* 1992;116:273-8.
- Siscovick DS, Schwartz SM, Grayston T, Tracy R, Kuller LH, Krommal RA. Antibody to *Chlamydia pneumoniae*, herpes simplex virus type 1, cytomegalovirus and incident myocardial infarction and coronary heart disease death: the cardiovascular health study. *Circulation* 1997;97(suppl 1):814.
- Glader CA, Boman J, Saikku P, Stenlund H, Weinehall L, Hallmanns, et al. The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing *Chlamydia pneumoniae*-specific IgG antibodies. *Eur Heart J* 2000;21:639-46.
- Von Hertzen L, Isoaho R, Kivela SL, Saikku P. Relation of *C pneumoniae* antibodies to ischaemic heart disease. *BMJ* 1999;1575-6.
- Ossewaarde JM, Feskens EJ, De Vries A, Vallinge CE, Kromhout D. *Chlamydia pneumoniae* is a risk factor for coronary heart disease in symptom-free elderly men, but *Helicobacter pylori* and cytomegalovirus are not. *Epidemiol Infect* 1998;120:93-9.
- Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated *Chlamydia pneumoniae* antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. *Circulation* 1997;96:404-7.
- Roivainen M, Viik-Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P, et al. Infections, inflammation and the risk of coronary heart disease. *Circulation* 2000;101:252-8.
- Danesh J, Youngman L, Clark S, Parish S, Peto R, Collins R. *Helicobacter pylori* infection and early onset myocardial infarction: case-control and sibling pairs study. *BMJ* 1999;319:1157-62.
- Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS study. *Eur Heart J* 1999;20:121-7.
- Gurfinkel E, Bozovich G, Daroca A, Beck A, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. *Lancet* 1997;350:404-7.
- Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for *Chlamydia pneumoniae* infection: the azithromycin in coronary artery disease: elimination of myocardial infection with chlamydia (ACADEMIC) study. *Circulation* 1999;99:1540-7.

(Accepted 6 June 2000)

Endpiece

I know him

You kill a man—that is easy ... it needs no skill. You can be certain of what you've done, you can judge death, but to save a man—that takes more than six years of training, and in the end you can never be quite sure it was you who saved him. Germs are killed by other germs. People just survive. There is not one patient whom I know for certain that I saved, but the man I killed—I know him.

Dr Hasselbacher in *Our Man in Havana* by Graham Greene, Penguin, 1962

Submitted by Alan P McGlennan, senior house officer in anaesthetics, Enfield

Commentary: Adjustment for potential confounders may have been taken too far

Robert West

Danesh and colleagues' study, based on the 24 British towns study, shows a weaker association between markers for chronic or past infection with *Chlamydia pneumoniae* and incident ischaemic heart disease than some earlier reports. The odds ratio comparing highest with lowest tertiles of IgG titres was 1.7 and highly significant before adjustment. It remained highly significant (1.6) after adjustment for age, town, smoking, and social class but reduced to 1.2 and became non-significant after adjustment for childhood social class. The authors include this last estimate in their statistical overview of 15 prospective studies.

These findings provide an opportunity to review the rationale underlying adjustment in analysis. The principles of adjusting (or standardisation) are essentially the same as those of matching when selecting controls in case control studies: to match for factors or characteristics known or previously shown to be causally associated with the disease.¹ With the wisdom of hindsight, when chains of causality have been shown experimentally, it is not difficult to recognise and distinguish causal confounders, associated markers, and unrelated factors or characteristics, but identification is harder during analysis and interpretation of observational studies. It is possible to overmatch when selecting controls and to overadjust in analysis.

A previous example, adjustment for birth weight in perinatal mortality, illustrates the point. We recommend adjustment for birth weight when comparing the performance of health authorities and hospitals (and doctors) so that like is compared with like and to compensate for the higher expected perinatal mortality in a hospital that admits more than its share of low birthweight babies.² However, in a study of the aetiology of perinatal mortality it would be inappropriate to adjust for birth weight, since low birth weight (light for dates or premature delivery) could be an indicator of the same disease process as the perinatal mortality itself.³ Adjusting for birth weight in an aetiological study of perinatal disease could be "throwing the baby out with the bathwater."

The analysis by Danesh and colleagues of the 24 towns study adjusts for both social class and childhood social class. Social class is a powerful epidemiological tool, and this United Kingdom measure is the envy of epidemiologists in many other countries. It is strongly associated with many diseases and is a useful proxy for exposure (occupational or environmental hazards, poverty, malnourishment, etc) and possibly for constitutional characteristics, but it is not a measure of exposure itself. Thus adjustment for social class, when we know little of the mechanism by which social class effects the disease under study, may be overadjustment.

In this study it is adjustment for childhood social class that removes the significance of the association (the "dose response," one of Bradford Hill's criteria for causality, although weakened, remains (see table 3)). In the 24 towns study childhood social class was estimated

from a composite of measures, including bathroom in house. Like the adult classification, childhood social class is a potential proxy for many possible exposures, including nutrition and hygiene, or for various constitutional characteristics. It might be argued that poor hygiene and nutrition in childhood (low childhood social class) allows early infection by *C pneumoniae* to become chronic, as indicated by raised IgG titres. It is perhaps appropriate to recall that, although tuberculosis was infectious among poorer people in urban slums, doctors and nurses in tuberculosis sanatoriums remained remarkably free of the disease.⁴ Associations between early antecedents, including childhood social class, and adult ischaemic heart disease are recognised,⁵ but there is poor understanding of the mechanisms by which childhood social class influences age at which ischaemic heart disease is manifest.

Until mechanisms are better understood, it seems wise to report associations without, as well as with, adjustment for childhood social class. Indeed, it could be argued that these associations should be summarised without, as well as with, adjustment for adult social class—if *C pneumoniae* might be one mechanism by which social class affects age of onset of clinical heart disease. These reservations notwithstanding, the statistical overview does suggest that any association between markers of chronic infection by this organism and fatal or non-fatal myocardial infarction is not strong.

University of Wales
College of
Medicine, Cardiff
CF4 4XN
Robert West
reader in
epidemiology

- 1 Rothman KJ. *Modern epidemiology*. Boston: Little Brown, 1986.
- 2 Chalmers I, Newcombe R, West RR, et al. Adjusted perinatal mortality rates in administrative areas of England and Wales. *Health Trends* 1978;10:24-9.
- 3 West RR. Perinatal and infant mortality in Wales: recent trends, inter-district variations and associations with socio-environmental characteristics. *Int J Epidemiol* 1988;17:392-6.
- 4 Hart PD, Wright GP. *Tuberculosis and social conditions in England*. London: National Association for the Prevention of Tuberculosis, 1939.
- 5 Barker DJP, Osmond C, Winter PD, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. *Lancet* 1989;ii:577-80.

Endpiece

Lord Moran on old age

Lord Moran, Churchill's doctor, who died in 1977 at the age of 94, had this to say about old age and dying: "Old people with slow thoughts pass beyond the doubts and fears and hesitations of their middle years into the silence of great age, and when at last death comes to them quietly they hardly know their friendly visitor. Arteries harden, blanchening the seat of reason; men see life dimly as through a film, and find on the brink of dissolution that peace that passeth all understanding."

Moran C. *The anatomy of courage*. Boston: Houghton Mifflin, 1967.

Submitted by Fred Charatan,
retired geriatric physician, Florida